Analytical Data
-
Gene name
HTR1F
- Application
-
Alternative Names
Serotonin receptor 1F
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P30939
-
Expression Region
1-366aa
-
Molecular Weight
60.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HTR1F, or 5-Hydroxytryptamine Receptor 1F, is a member of the serotonin receptor family, which plays a crucial role in various neurological processes. Research into HTR1F is driven by its potential implications in neuropsychiatric disorders, including anxiety, depression, and schizophrenia. Understanding its structure and function is essential for developing targeted therapies that can better address these conditions. The receptor's ability to modulate neurotransmitter release and influence neural signaling pathways positions it as a promising target for pharmacological intervention. Recent studies have focused on the recombinant expression of HTR1F proteins, which allows for detailed examination of their properties through bioassays, binding studies, and structural analyses. These investigations aim to elucidate the receptor's activation mechanisms, signaling dynamics, and interaction with different ligands, which can pave the way for novel treatment strategies for mood disorders and other related health issues. By advancing our knowledge of HTR1F through recombinant protein research, scientists hope to unlock new avenues for the development of selective and effective pharmacotherapies that can mitigate the burden of serotonin-related disorders.
